Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Results of a Phase II Open-Label Trial of Bortezomib in Patients with Multiple Myeloma Who Have Undergone High-Dose Melphalan Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation and Failed to Achieve a Complete Response

Robert M. Rifkin, MD, Gary Spitzer, MD, Andrew Greenspan, MD, John F. Schwerkoske, MD, Romeo A. Mandanas, MD, FACP, Joe Stephenson, MD, George T. Kannarkat, Feng Zhan, PhD, Lina Asmar, PhD, Roy Beveridge, MD

Blood (2008) 112 (11): 2780.

https://doi.org/10.1182/blood.V112.11.2780.2780

Published: 2008

Journal Articles

Results of a Phase II Study of Bortezomib in Patients with Relapsed or Refractory Indolent Lymphoma.

Nicholas Di Bella, MD, Raymond Taetle, MD, Kathryn S. Kolibaba, MD, Thomas E Boyd, MD, Robert N Raju, MD, David N Barrera, DO, Ernest Cochran, MD, Philip Dien, MD, David Hakimian, MD, Roger M. Lyons, MD, Peter J Schlegel, MD, Svetislava J Vukelja, MD, Julie Boston, RN, Kristi A Boehm, MS, Yunfei Wang, MS, Lina Asmar, PhD

Blood (2008) 112 (11): 1572.

https://doi.org/10.1182/blood.V112.11.1572.1572

Published: 2008

Journal Articles

Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab Vs. Pentostatin, Cyclophosphamide, and Rituximab in B-Cell Chronic Lymphocytic Leukemia

Craig Reynolds, MD, Nicholas Di Bella, MD, Roger M. Lyons, MD, William J Hyman, MD, Gary L. Lee, MD, Donald A Richards, MD, PhD, Gerald J. Robbins, MD, Mark Vellek, MD, Kristi A Boehm, MS, Feng Zhan, PhD, Lina Asmar, PhD

Blood (2008) 112 (11): 327.

https://doi.org/10.1182/blood.V112.11.327.327

Published: 2008

Journal Articles

Results of a Randomized Phase II Trial of Pegfilgrastim Versus Filgrastim To Treat Neutropenia Post-Autologous Peripheral Blood Stem Cell Transplant (PBSCT) in Patients with Non-Hodgkin’s Lymphoma (NHL).

Robert Rifkin, MD, Roy Beveridge, MD, Gary Spitzer, MD, Gregory Orloff, MD, Romeo Mandanas, MD, Dean McGaughey, MD, Mark Brunvand, MD, Feng Zhan, PhD, Kristi A. Boehm, MS, Lina Asmar, PhD

Blood (2007) 110 (11): 4936.

https://doi.org/10.1182/blood.V110.11.4936.4936

Published: 2007

Journal Articles

Interim Analysis of a Phase II Trial of Bortezomib in Patients with Multiple Myeloma Who Failed To Achieve a Complete Response to Autologous Peripheral Blood Stem Cell Transplantation.

Robert M. Rifkin, MD, Roy A. Beveridge, MD, Mark W. Brunvand, MD, Gary Spitzer, MD, Boehm A. Kristi, MS, Mary Ann Rauch, BS, Feng Zhan, PhD, Lina Asmar, PhD

Blood (2005) 106 (11): 5176.

https://doi.org/10.1182/blood.V106.11.5176.5176

Published: 2005

NARROW

Results of a Phase II Open-Label Trial of Bortezomib in Patients with Multiple Myeloma Who Have Undergone High-Dose Melphalan Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation and Failed to Achieve a Complete Response

Results of a Phase II Study of Bortezomib in Patients with Relapsed or Refractory Indolent Lymphoma.

Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab Vs. Pentostatin, Cyclophosphamide, and Rituximab in B-Cell Chronic Lymphocytic Leukemia

Results of a Randomized Phase II Trial of Pegfilgrastim Versus Filgrastim To Treat Neutropenia Post-Autologous Peripheral Blood Stem Cell Transplant (PBSCT) in Patients with Non-Hodgkin’s Lymphoma (NHL).

Interim Analysis of a Phase II Trial of Bortezomib in Patients with Multiple Myeloma Who Failed To Achieve a Complete Response to Autologous Peripheral Blood Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Results of a Phase II Open-Label Trial of Bortezomib in Patients with Multiple Myeloma Who Have Undergone High-Dose Melphalan Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation and Failed to Achieve a Complete Response

Results of a Phase II Study of Bortezomib in Patients with Relapsed or Refractory Indolent Lymphoma.

Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab Vs. Pentostatin, Cyclophosphamide, and Rituximab in B-Cell Chronic Lymphocytic Leukemia

Results of a Randomized Phase II Trial of Pegfilgrastim Versus Filgrastim To Treat Neutropenia Post-Autologous Peripheral Blood Stem Cell Transplant (PBSCT) in Patients with Non-Hodgkin’s Lymphoma (NHL).

Interim Analysis of a Phase II Trial of Bortezomib in Patients with Multiple Myeloma Who Failed To Achieve a Complete Response to Autologous Peripheral Blood Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only